NCT06332430

Intratumoral CAN2109 in Subjects With Solid Tumors

A Phase 1, Dose Escalation, Open-Label Study of Intratumoral CAN2109 in Subjects With Unresectable or Metastatic Advanced Solid Tumors.

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 27 (estimated)
• Sponsor: Canwell Biotech Limited · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A phase 1, dose escalation, open-label study of intratumoral CAN2109 in subjects with unstable or metastatic advanced solid tumors or lymphomas.

Detailed description

The scope of the study is to evaluate the safety of CAN2109 in humans, explore its safety, efficacy and collect data on the pharmacokinetics, as well as on the pharmacodynamic effect of the drug on the immune system locally and systemically, and on tumor markers.

Conditions

• Solid Tumor
• Lymphoma

Interventions

Type	Name	Description
DRUG	CAN2109	CAN2109 IT injection (once every 3 weeks)

Timeline

• Start date: 2024-05-28
• Primary completion: 2025-05-30
• Completion: 2026-05-30
• First posted: 2024-03-27
• Last updated: 2024-12-19

Locations

1 site across 1 country: China